SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending ahead of earnings, with much discussion focused on whether it can justify its high valuation amidst excitement around AI. Some are anticipating a breakout based on partnerships and confidence from leadership, while others are wary of a potential pullback and overblown hype. The community is closely watching for guidance and any surprise announcements.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending as investors anticipate the upcoming earnings report, with the community split between bullish and bearish expectations. Discussions revolve around potential growth catalysts, such as new weight-loss and menopause treatments, and whether the company can maintain its growth trajectory. Some traders are wary of potential post-earnings volatility, while others are closely watching for a possible short squeeze amid high short interest.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors anticipate upcoming earnings and potential FDA updates, specifically regarding its gene therapy Elevidys. The community is actively discussing predictions for the earnings report and speculating on the likelihood of positive surprises. Traders are also closely monitoring the overall healthcare sector and potential buyout scenarios for the company.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to volatility potentially linked to news from competitors like IREN and Cipher, impacting sentiment around AI infrastructure deals. The community is debating whether recent price drops represent a buying opportunity or signal deeper issues before earnings, with some attributing the volatility to algo trading and short attacks. Despite the uncertainty, the broader context of increasing AI infrastructure demand and a large Microsoft contract provides some support for the stock.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as the community rallies around its meme-driven culture and real-world partnerships, including sponsorships in sports and streaming. Community members express enthusiasm, highlighting the token's active presence and potential for growth. The focus remains on community support and shared bullish sentiment.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending following news of a major deal with Amazon Web Services to provide AI infrastructure. The community is discussing the implications of this partnership, potential price targets, and the broader impact on the AI data center sector. Many see this as a pivotal moment for CIFR, drawing comparisons to other key players in the space.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors eagerly await earnings and anticipate further details on their partnership with Palantir, particularly how it will accelerate AI adoption for businesses. The community is buzzing with excitement, with many speculating on a significant run and buyout potential, fueled by insider buying and positive sentiment around the company's transformation. Bullish investors express confidence in Lumen's strategic shift towards AI-driven connectivity and NaaS, viewing it as a key player in the ongoing AI revolution.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as investors await the FDA decision on the expanded indication for Revuforj in relapsed or refractory NPM1 mutated acute myeloid leukemia. The community is discussing the potential for a buyout, especially by Incyte, as well as comparing Revuforj's prospects against competitors. Some traders are anticipating a post-approval sell-off, while others are optimistic about the drug's commercial potential and long-term value.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors anticipate upcoming earnings and debate the company's valuation. Community members are discussing potential price movements, with some eyeing the $100 mark, while others assess the impact of autonomous vehicle partnerships and the broader ride-sharing landscape on Uber's growth.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors digest recent performance and debate the company's future direction, with some community members pointing to potential downside while others see a buying opportunity. Discussions revolve around the impact of tariffs, brand strategy, and overall market conditions. Some traders are eyeing technical levels and potential breakout setups, while others express frustration with the stock's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immutep's Head & Neck Cancer Therapy Excels

Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has been selected to present its late-breaking abstract at the ESMO Congress 2024, detaili...

Immutep Ltd (PRRUF) Gets a Buy from Canaccord Genuity

In a report released on August 16, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Immutep Ltd (PRRUF Research Report), with a pr...

Immutep Readies Phase III Lung Cancer Trial

Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has received positive feedback from the FDA for their upcoming Phase III trial, TACTI-004...

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF Research Report) and Immutep (IMMP Re...

Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.6% in March

Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,140,000 shares, an increase...

Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average of $2.35

Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.35 and traded as high as $2.47. Immutep...

Immutep announces first clinical data from 90mg dosing of efti

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 53.4% in January

Immutep Limited (NASDAQ:IMMP  Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Immutep Limited - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

IMMP
Immutep LTD ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMMP News

IMMPImmutep LTD ADR